Terminated PHASE1 INTERVENTIONAL 4-arm NCT05252416

(VELA) Study of BLU-222 in Advanced Solid Tumors

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors

Sponsor: Blueprint Medicines Corporation

Conditions Advanced Solid Tumors CCNE1 Amplification Carcinosarcoma Endometrial Cancer Esophageal Adenocarcinoma Gastric Cancer HER2-negative Breast Cancer HR+ Breast Cancer Ovarian Cancer

Interventions BLU-222 Carboplatin Fulvestrant Ribociclib

Updated 15 times since 2022 Last updated: Nov 24, 2025 Started: Apr 7, 2022 Primary completion: Jul 4, 2025 Completion: Jul 4, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns.

Other terminated trials from Blueprint Medicines Corporation

More terminations from Blueprint Medicines Corporation

Other Advanced Solid Tumors trials with similar outcome

Browse all Advanced Solid Tumors trials

A PHASE1 clinical study on Advanced Solid Tumors and CCNE1 Amplification, this trial is terminated or withdrawn. The trial is conducted by Blueprint Medicines Corporation and has accumulated 15 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

15 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated · Phase: PHASE1/PHASE2 → PHASE1
Sep 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 10 earlier versions

May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — May 2023 [monthly]

Recruiting PHASE1_PHASE2
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Dec 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Blueprint Medicines Corporation

Data source: Blueprint Medicines Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Chapel Hill, United States , Charlottesville, United States , Chicago, United States , Detroit, United States , Houston, United States , Little Rock, United States , London, United Kingdom , Milan, Italy and 9 more locations